Navigation Links
Swiss study suggests surgery may offer best chance of long-term prostate cancer survival
Date:10/8/2007

A study from Switzerland suggests that men who have surgery for prostate cancer appear less likely to die of the disease within 10 years than men who choose other treatment options, especially if they are younger or have cancers with certain tumor cell characteristics, according to a report in the Oct. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Prostate cancer treatments are still being debated because they have not yet been compared in a randomized trial, in which men would be randomly assigned to one treatment or another, according to background information in the article. Therefore, treatment choice is strongly influenced by patient and physician personal preferences and experiences, the authors write.

Arnaud Merglen, M.D., of Geneva University, Switzerland, and colleagues used data from the Geneva Cancer Registry to assess all 844 patients diagnosed with localized (not yet spread) prostate cancer in Geneva between 1989 and 1998. Of those men, 158 received prostatectomy, or surgery to remove all or part of the prostate; 205 had radiation treatment (radiotherapy); 378 chose watchful waiting, which entails active follow-up and treatment if the disease progresses; 72 underwent hormone therapy; and 31 had another type of therapy.

The average follow-up was 6.7 years (range zero to 15.8 years), and 47 patients (5.6 percent) left Geneva and the study before the study concluded.

At 10 years, patients treated with radiotherapy or watchful waiting had a significantly increased risk of death from prostate cancer compared with patients who underwent prostatectomy, the authors write. Ten-year survival rates from prostate cancer were 83 percent for prostatectomy, 75 percent for radiotherapy, 72 percent for watchful waiting, 41 percent for hormone therapy and 71 percent for other treatment. The increased mortality associated with radiotherapy and watchful waiting was primarily observed in patients younger than 70 years and in patients with poorly differentiated tumors, or tumors that have certain cellular characteristics and are more likely to spread aggressively.

Until clinical trials provide conclusive evidence, physicians and patients should be informed of these results and their limitations, the authors conclude. '/>"/>

Contact: Christine Bouchardy
christine.bouchardymagnin@imsp.unige.ch
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Swiss Researchers Isolate Hair-Raising Stem Cells
2. Euthanasia To Be Permitted In Swiss Hospital
3. Swiss Group Appeals Invocation of Euthanasia Option For The Severely Depressed
4. Rural Canadians travel far for specialists: study
5. A new study surpasses Gene Therapy Hurdle
6. Tomato Sauce reduces Cancer Risk- Study
7. A question on study of Adult Stem Cell
8. Study on obesity and heart failure
9. National Lung Study in the process
10. Marijuana gateway theory strengthened by study of twins
11. Old theory of adaptation confirmed by new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: